Nurix End Period Cash Flow from 2010 to 2025

NRIX Stock  USD 20.02  0.37  1.88%   
Nurix Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 77.5 M in 2025. During the period from 2010 to 2025, Nurix Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.60 and arithmetic mean of  54,886,004. View All Fundamentals
 
End Period Cash Flow  
First Reported
2019-05-31
Previous Quarter
99.9 M
Current Value
110.9 M
Quarterly Volatility
59.4 M
 
Covid
Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 326 K, Net Interest Income of 23.8 M or Interest Income of 23.8 M, as well as many indicators such as Price To Sales Ratio of 24.85, Dividend Yield of 0.0 or PTB Ratio of 2.66. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Nurix Therapeutics Correlation against competitors.
For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Latest Nurix Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Nurix Therapeutics over the last few years. It is Nurix Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nurix Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Nurix End Period Cash Flow Regression Statistics

Arithmetic Mean54,886,004
Geometric Mean44,770,810
Coefficient Of Variation68.28
Mean Deviation31,612,505
Median34,986,000
Standard Deviation37,475,374
Sample Variance1404.4T
Range101.8M
R-Value0.77
Mean Square Error602T
R-Squared0.60
Significance0.0004
Slope6,096,700
Total Sum of Squares21066.1T

Nurix End Period Cash Flow History

202577.5 M
2024127.5 M
2023110.9 M
202255.5 M
202165.4 M
202080.8 M
2019119.5 M

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow127.5 M77.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.